Our Leadership Team

Simon Allen

Chief Business Officer
Simon Allen joined Ambrx as Chief Business Officer and brings more than 25 years of industry experience and success both as a scientist and a business executive. Previously, Mr. Allen was Chief Executive Officer (CEO) at CohBar, Inc. where he transitioned the company to the clinical stage, listed it on NASDAQ and made the 2018 Russell 2000 Index. Mr. Allen also lead business development initiatives at Ambrx from 2010 – 2015 where he established multiple collaborations with Bristol-Myers Squibb, Merck, Astellas, Eli Lilly, and Zhejiang Medicine that helped accelerate and mature an expanding pipeline as well as realizing over $140 million in non-dilutive revenue and over $1 billion in potential milestone payments. Mr. Allen was also CEO of Kalypsys Inc., and Chief Commercial Officer of CovX Inc. (acquired by Pfizer for over $600M). In the past, Mr. Allen has held various business and corporate development positions within the Biopharma industry, worked as a healthcare analyst within the financial sector, and began his career developing anti-viral therapies as a Research Biologist at Gilead Sciences. Mr. Allen holds a B.Sc. degree in biochemistry and genetics from the University of Sydney and an M.B.A. from the Australian Graduate School of Management.